Better Health for All

Amarin's core product, Vascepa/Vazkepa, is dedicated to improving cardiovascular health, with the company's entire business focused on stopping cardiovascular disease from being a leading cause of death.

Clinical trials demonstrated that Vascepa, when added to statin therapy, reduced the chance of a life-threatening cardiovascular event by 25% and showed a 17% regression of low attenuation plaque volume over 18 months. However, the product is associated with an increased risk of adverse events, including bleeding (12% vs 10% for placebo) and atrial fibrillation requiring hospitalization (3% vs 2% for placebo), as well as other common adverse reactions. The company provides a savings card program, allowing eligible commercially insured or uninsured patients to pay as little as $9 for a 90-day supply, with potential savings of up to $450 for a 90-day prescription. Despite these efforts, Italy's AIFA Pricing & Reimbursement Committee issued a negative decision on VAZKEPA reimbursement. The product is indicated for adult patients with elevated triglyceride levels (≥150 mg/dL or ≥500 mg/dL) and established cardiovascular disease or diabetes, reaching a specific high-risk population. Amarin discloses risks in its SEC filings and mentions reporting adverse events. The company states it is relentless in its pursuit of scientific breakthroughs and advancing innovation in cardiovascular disease. Clinical trials like REDUCE-IT involved over 8,000 patients across 400+ sites in 11 countries, including 1,600 Dutch patients across 40+ sites, and were conducted based on a special protocol assessment agreement with the FDA.

Fair Money & Economic Opportunity

Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing therapeutics for cardiovascular health.

The provided articles detail the company's financial performance, product information (Vascepa savings programs), and regulatory approvals for its medication. The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess financial institutions that lend, insure, move, or store money. As Amarin's core business lies outside financial services, and none of the articles provide specific, concrete data points related to financial products, lending, or financial inclusion initiatives, all KPIs are omitted due to a lack of relevant evidence.

Fair Pay & Worker Respect

Amarin Corporation plc's CEO to median employee pay ratio was 21:1 in 2024.

The company's employee engagement score is 70 out of 100, based on employee ratings. Executive officers are eligible to participate in all employee benefit plans, including medical, dental, group life, disability, and accidental death and dismemberment insurance, on the same basis as other employees.

Fair Trade & Ethical Sourcing

No specific quantitative data was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While the company mentions having a Partner Code of Ethics,

Supply Chain Management Policy, Procurement policy, Human Rights Policy, and a Modern Slavery Act Statement, and states a commitment to ethical standards and sustainable practices, there is no evidence regarding the percentage of fair-trade certified spend, supplier audit frequency, number of forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, percentage of contracts with ethical clauses, share of spend on high-risk materials, or supplier diversity spend.

Kind to Animals

Amarin states it strives to comply with the 3Rs (Replacement, Reduction, Refinement) and aims to develop technologies to approach the abandonment of animal use.

However, this is a statement of intent and commitment in principle, lacking measurable goals or specific accountability for its implementation.

Respect for Cultures & Communities

The company has established 12 formal partnerships with educational institutions and organizations.

It also has a policy to resolve substantiated and significant complaints within 30 business days from the date of receipt. In cases of force majeure requiring more than 30 days, progress updates are provided every 15 business days.

Zero Waste & Sustainable Products

Amarin Corporation plc (AMRN.US) operates primarily as a pharmaceutical company that leases its facilities and does not manufacture or store its own products, as noted in its 2016 annual report, suggesting a minimal direct environmental footprint.

While a 2024 Sustainability Report is mentioned, its contents are not provided. General sustainability strategies and policies for 2023-2030 are in place, focusing on green procurement, resource efficiency, and selecting sustainable materials across the value chain. However, these are high-level statements of intent or strategy, not concrete evidence of implemented actions or measurable outcomes for specific waste or product sustainability KPIs. One article mentions that 'scraps of paper, film, and used aluminum molds' from a printing production facility are sold to reuse companies, which indicates some waste diversion. However, this information pertains to a specific production activity (printing) and does not provide a company-wide waste diversion rate or specify if this activity is representative of Amarin's overall operations or product lifecycle. Without quantitative data or company-wide scope for any of the defined KPIs, no specific scores can be assigned.